InMed Pharmaceuticals (INM) Intangibles (2020 - 2026)

InMed Pharmaceuticals has reported Intangibles for 7 years, with the latest figure at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles changed 0.0% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (changed 0.0% YoY), and the FY2025 full-year result was $2.9 million, changed 0.0% from the prior year.
• Intangibles for Q1 2026 stood at $2.9 million, up from $1.5 million in the prior quarter.
• The five-year high for Intangibles was $2.9 million in Q1 2024, with the low at $300000.0 in Q2 2023.
• Historically, Intangibles has averaged $2.2 million across 5 years, with a median of $2.1 million in 2022.
• Annual changes were most pronounced in 2023 — Intangibles plunged 85.77% — and 2024, when it surged 875.81%.
• InMed Pharmaceuticals' Intangibles stood at $1.7 million in 2022, then climbed by 7.36% to $1.9 million in 2023, then soared by 57.03% to $2.9 million in 2024, then slumped by 47.44% to $1.5 million in 2025, then surged by 90.27% to $2.9 million in 2026.
• The last three Intangibles figures came in at $2.9 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.